Compare ALEMBIC PHARMA with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ORCHID PHARMA - Comparison Results

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ORCHID PHARMA ALEMBIC PHARMA/
ORCHID PHARMA
 
P/E (TTM) x 16.4 -22.4 - View Chart
P/BV x 6.5 6.4 101.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALEMBIC PHARMA   ORCHID PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ORCHID PHARMA
Sep-13
ALEMBIC PHARMA/
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs664194 342.3%   
Low Rs41235 1,178.3%   
Sales per share (Unadj.) Rs208.7276.5 75.5%  
Earnings per share (Unadj.) Rs31.0-79.2 -39.1%  
Cash flow per share (Unadj.) Rs37.1-43.5 -85.4%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.253.9 267.4%  
Shares outstanding (eoy) m188.5270.45 267.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.4 622.6%   
Avg P/E ratio x17.4-1.4 -1,201.1%  
P/CF ratio (eoy) x14.5-2.6 -550.4%  
Price / Book Value ratio x3.72.1 175.8%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,4618,067 1,257.8%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m7,4672,527 295.5%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m39,34719,477 202.0%  
Other income Rs m94407 23.0%   
Total revenues Rs m39,44119,884 198.4%   
Gross profit Rs m8,7361,103 792.3%  
Depreciation Rs m1,1522,519 45.7%   
Interest Rs m1845,227 3.5%   
Profit before tax Rs m7,493-6,236 -120.2%   
Minority Interest Rs m1120 54.8%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,568-125 -1,252.0%   
Profit after tax Rs m5,844-5,580 -104.7%  
Gross profit margin %22.25.7 392.2%  
Effective tax rate %20.92.0 1,042.0%   
Net profit margin %14.9-28.7 -51.8%  
BALANCE SHEET DATA
Current assets Rs m19,57711,014 177.7%   
Current liabilities Rs m14,89632,060 46.5%   
Net working cap to sales %11.9-108.1 -11.0%  
Current ratio x1.30.3 382.6%  
Inventory Days Days9095 94.6%  
Debtors Days Days4534 135.2%  
Net fixed assets Rs m27,09729,440 92.0%   
Share capital Rs m377705 53.5%   
"Free" reserves Rs m26,8112,043 1,312.6%   
Net worth Rs m27,1883,800 715.5%   
Long term debt Rs m4,9939,018 55.4%   
Total assets Rs m47,77846,510 102.7%  
Interest coverage x41.7-0.2 -21,593.7%   
Debt to equity ratio x0.22.4 7.7%  
Sales to assets ratio x0.80.4 196.7%   
Return on assets %12.6-0.8 -1,660.0%  
Return on equity %21.5-146.9 -14.6%  
Return on capital %23.6-3.7 -632.0%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m19,4537,513 258.9%   
Fx outflow Rs m6,0655,649 107.4%   
Net fx Rs m13,3881,865 718.0%   
CASH FLOW
From Operations Rs m8,1201,682 482.8%  
From Investments Rs m-7,556-9,860 76.6%  
From Financial Activity Rs m5906,644 8.9%  
Net Cashflow Rs m1,153-1,535 -75.1%  

Share Holding

Indian Promoters % 74.1 32.3 229.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 4.6 63.0%  
FIIs % 9.1 3.3 275.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 13.9 55.3 25.1%  
Shareholders   49,328 84,811 58.2%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NEULAND LABS  WYETH  ABBOTT INDIA  ALEMBIC  DR. REDDYS LAB  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 22, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - CIPLA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS